Acute Myeloid Leukemia Research Today is a free monthly online journal that collates and summarizes the latest research about Acute Myeloid Leukemia, including details on aml, symptoms, treatment, information.

Volume 1 (2004), Issue 5 (December)

1. Expression profiling of murine acute promyelocytic leukemia cells reveals multiple model-dependent progression signatures.
   Mol Cell Biol, 24(24): 10882-93. [Abstract] [Full-text]
2. Complex translocation (8;12;21): a new variant of t(8;21) in acute myeloid leukemia.
   Cancer Genet Cytogenet, 155(2): 138-42. [Abstract] [Full-text]
3. Mutation of CEBPA in familial acute myeloid leukemia.
   N Engl J Med, 351(23): 2403-7. [Abstract] [Full-text]
4. Regulation of the cyclin A1 protein is associated with its differential subcellular localization in hematopoietic and leukemic cells.
   Oncogene, 23(56): 9082-9. [Abstract] [Full-text]
5. Parameters for predicting allogeneic PBSCT outcome of acute myeloid leukemia: cytogenetics at presentation versus disease status at transplantation.
   Ann Hematol, 84(1): 25-32. [Abstract] [Full-text]
6. Genetic variation in XPD predicts treatment outcome and risk of acute myeloid leukemia following chemotherapy.
   Blood, 104(13): 3872-7. [Abstract] [Full-text]
7. Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells.
   Blood, 104(13): 4202-9. [Abstract] [Full-text]
8. Normal and oncogenic FLT3.
   Cell Mol Life Sci, 61(23): 2932-8. [Abstract] [Full-text]
9. Detection of neuroblastoma cells in bone marrow and peripheral blood by different techniques: accuracy and relationship with clinical features of patients.
   Clin Cancer Res, 10(23): 7978-85. [Abstract] [Full-text]
10. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias.
    Clin Cancer Res, 10(23): 7896-902. [Abstract] [Full-text]
11. IL-2/B7.1 (CD80) fusagene transduction of AML blasts by a self-inactivating lentiviral vector stimulates T cell responses in vitro: a strategy to generate whole cell vaccines for AML.
    Mol Ther, 11(1): 120-31. [Abstract] [Full-text]
12. Mercury induces multidrug resistance-associated protein gene through p38 mitogen-activated protein kinase.
    Toxicol Lett, 155(1): 143-50. [Abstract] [Full-text]
13. Deletion of an AML1-ETO C-terminal NcoR/SMRT-interacting region strongly induces leukemia development.
    Proc Natl Acad Sci U S A, 101(49): 17186-91. [Abstract] [Full-text]
14. Enhancement of hematopoietic stem cell repopulating capacity and self-renewal in the absence of the transcription factor C/EBP alpha.
    Immunity, 21(6): 853-63. [Abstract] [Full-text]
15. Activation of HLXB9 by juxtaposition with MYB via formation of t(6;7)(q23;q36) in an AML-M4 cell line (GDM-1).
    Genes Chromosomes Cancer, 42(2): 170-8. [Abstract] [Full-text]
16. The serine-threonine kinase MNK1 is post-translationally stabilized by PML-RARalpha and regulates differentiation of hematopoietic cells.
    Oncogene, 23(57): 9162-72. [Abstract] [Full-text]
17. Induction of gene expression by 5-Aza-2'-deoxycytidine in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) but not epithelial cells by DNA-methylation-dependent and -independent mechanisms.
    Leukemia, 19(1): 103-11. [Abstract] [Full-text]
18. Development of a D-FISH method to detect DEK/CAN fusion resulting from t(6;9)(p23;q34) in patients with acute myelogenous leukemia.
    Leukemia, 19(1): 126-31. [Abstract] [Full-text]
19. Affinity binding of cells to cryogel adsorbents with immobilized specific ligands: effect of ligand coupling and matrix architecture.
    J Mol Recognit, 18(1): 84-93. [Abstract] [Full-text]
20. Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling.
    Oncogene, 23(58): 9381-91. [Abstract] [Full-text]
21. Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells.
    J Pharmacol Exp Ther, 312(1): 346-54. [Abstract] [Full-text]
22. A differential gene expression profile reveals overexpression of RUNX1/AML1 in invasive endometrioid carcinoma.
    Cancer Res, 64(24): 8846-53. [Abstract] [Full-text]
23. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
    Cancer Res, 64(24): 8816-20. [Abstract] [Full-text]
24. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors.
    Cancer Cell, 6(6): 587-96. [Abstract] [Full-text]
25. KIR-ligand mismatch in allogeneic hematopoietic stem cell transplantation.
    Mol Immunol, 42(4): 531-4. [Abstract] [Full-text]
26. In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleukin 8.
    Leuk Res, 29(2): 185-96. [Abstract] [Full-text]
27. The expression of iASPP in acute leukemias.
    Leuk Res, 29(2): 179-83. [Abstract] [Full-text]
28. Bone marrow CD34+ cell count is predictive for adequate peripheral progenitor cell collection.
    Leuk Res, 29(2): 159-63. [Abstract] [Full-text]
29. BCRP mRNA expression v. clinical outcome in 40 adult AML patients.
    Leuk Res, 29(2): 141-6. [Abstract] [Full-text]
30. Analysis of times to repeated events in two-arm randomized trials with noncompliance and dependent censoring.
    Biometrics, 60(4): 965-76. [Abstract] [Full-text]
31. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group.
    J Clin Oncol, 22(24): 4926-33. [Abstract] [Full-text]
32. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412.
    Blood, 105(1): 54-60. [Abstract] [Full-text]
33. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
    Blood, 105(1): 335-40. [Abstract] [Full-text]
34. Physical and functional link of the leukemia-associated factors AML1 and PML.
    Blood, 105(1): 292-300. [Abstract] [Full-text]
35. Enforced expression of an Flt3 internal tandem duplication in human CD34+ cells confers properties of self-renewal and enhanced erythropoiesis.
    Blood, 105(1): 77-84. [Abstract] [Full-text]
36. Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses.
    Blood, 105(1): 397-404. [Abstract] [Full-text]
37. Coculture of native human acute myelogenous leukemia blasts with fibroblasts and osteoblasts results in an increase of vascular endothelial growth factor levels.
    Eur J Haematol, 74(1): 24-34. [Abstract] [Full-text]
38. Conditioning with targeted busulfan for autologous peripheral blood stem cells transplantation for acute myelogenous leukemia in an XYY male.
    Am J Hematol, 78(1): 55-8. [Abstract] [Full-text]
39. Sample size calculation for multiple testing in microarray data analysis.
    Biostatistics, 6(1): 157-69. [Abstract] [Full-text]
40. The 'miss rate' for the analysis of gene expression data.
    Biostatistics, 6(1): 111-7. [Abstract] [Full-text]
41. Acute myeloid leukemia in the elderly: etoposide when anthracyclins are contraindicated.
    Leuk Lymphoma, 46(3): 401-4. [Abstract] [Full-text]
42. Prognostic features for response and survival in elderly patients with de novo acute myeloid leukemia treated with mitoxantrone and intermediate dose cytarabine.
    Leuk Lymphoma, 46(3): 367-75. [Abstract] [Full-text]
43. Substrate cycles and drug resistance to 1-beta-D-arabinofuranosylcytosine (araC).
    Leuk Lymphoma, 46(3): 335-46. [Abstract] [Full-text]
44. Biological effects of Atra and Arsenic Trioxide on short term cultures of non-M3 leukemic blasts.
    Leuk Lymphoma, 46(2): 257-63. [Abstract] [Full-text]
45. The Kasumi-1 cell line: a t(8;21)-kit mutant model for acute myeloid leukemia.
    Leuk Lymphoma, 46(2): 247-55. [Abstract] [Full-text]
46. Recurrent steroid-responsive pancreatitis associated with myelodysplastic syndrome and transformations.
    Leuk Lymphoma, 46(1): 151-4. [Abstract] [Full-text]
47. Daunorubicin efflux assay in determining multidrug resistance of patients with acute myeloid leukemia.
    Leuk Lymphoma, 46(1): 63-70. [Abstract] [Full-text]
48. Intensified induction chemotherapy in adult acute myeloid leukemia followed by high-dose chemotherapy and autologous peripheral blood stem cell transplantation: an Eastern Cooperative Oncology Group trial (E4995).
    Leuk Lymphoma, 46(1): 55-61. [Abstract] [Full-text]
49. Second neoplasms in chronic lymphocytic leukemia: incidence and pathogenesis with emphasis on the role of different therapies.
    Leuk Lymphoma, 46(1): 49-54. [Abstract] [Full-text]
50. Evaluation of telomerase mRNA (hTERT) in childhood acute leukemia.
    Leuk Lymphoma, 45(12): 2477-80. [Abstract] [Full-text]
51. Targeted busulfan and cyclophosphamide as compared to busulfan and TBI as preparative regimens for transplantation in patients with advanced MDS or transformation to AML.
    Leuk Lymphoma, 45(12): 2409-17. [Abstract] [Full-text]
52. Membranous nephropathy associated with acute myeloid leukemia.
    Transplant Proc, 36(9): 2618-9. [Abstract] [Full-text]
53. Pretransplantation induction chemotherapy and posttransplantation relapse in patients with advanced myelodysplastic syndrome.
    Biol Blood Marrow Transplant, 11(1): 65-73. [Abstract] [Full-text]
54. Methylation of histones in myeloid leukemias as a potential marker of granulocyte abnormalities.
    J Leukoc Biol, 77(1): 100-11. [Abstract] [Full-text]
55. EVI1 abrogates interferon-alpha response by selectively blocking PML induction.
    J Biol Chem, 280(1): 428-36. [Abstract] [Full-text]

© 2004-2008 Acute Myeloid Leukemia Research Today. All Rights Reserved.